NASDAQ: RENB - Renovaro Biosciences Inc.

六个月盈利: +19.76%
股息率: 0.00%
部门: Healthcare

促销时间表 Renovaro Biosciences Inc.

先进的时间表 简单图表
Financial Markets by TradingView

关于公司 Renovaro Biosciences Inc.

Renovaro Biosciences Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer. The company's product pipeline includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a gene therapy curative treatment for HBV.

更多详情
It develops ENOB-DC-11, an allogeneic dendritic cell therapeutic vaccine for solid tumors; ENOB-DC-12-XX, allogeneic dendritic cell therapeutic vaccine for other solid tumors; and ENOB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. Enochian Biosciences, Inc. has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Enochian Biosciences, Inc. and changed its name to Renovaro Biosciences Inc. in August 2023. The company was incorporated in 2017 and is headquartered in Los Angeles, California.
添加到比较列表
添加到观察列表
添加到投资组合
添加价格通知

IPO date 2015-02-02
ISIN US29350E1047
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.renovarobio.com
Цена ао 0.674
每日价格变化: -10.95% (0.65)
每周价格变化: -17.43% (0.701)
每月价格变化: -51.36% (1.19)
3个月内价格变化: -36.89% (0.9171)
六个月内的价格变化: +19.76% (0.4833)
每年价格变化: -78.16% (2.65)
3年内价格变化: -90.77% (6.27)
5年内价格变化: -84.27% (3.68)
年初以来价格变化: -33.52% (0.8706)
所有参数

低估

姓名 意义 年级
P/S 0 0
P/BV 1.16 9
P/E 0 0
EV/EBITDA -1.97 0
全部的: 3.13

效率

姓名 意义 年级
ROA, % -72.84 0
ROE, % -90.37 0
全部的: 0

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0 0
全部的: 0

责任

姓名 意义 年级
Debt/EBITDA -0.0476 10
全部的: 10

成长冲动

姓名 意义 年级
盈利能力 Revenue, % 42.56 6
盈利能力 Ebitda, % 609.97 10
盈利能力 EPS, % 241.32 10
全部的: 7.4
更多详情

机构 体积 分享, %
Vanguard Group Inc 390107 1.01
Morgan Stanley 362978 0.94
Geode Capital Management, LLC 362409 0.93
Blackrock Inc. 304656 0.79
Millennium Management LLC 126314 0.33
Susquehanna International Group, LLP 119459 0.31
State Street Corporation 97687 0.25
Northern Trust Corporation 88101 0.23
683 Capital Management LLC 73706 0.19
Qube Research & Technologies Ltd 67978 0.18

ETF分享, %本年盈利能力, %股息, %
iShares Micro-Cap ETF 0.00641 17.09 1.54048
iShares Russell 2000 Growth ETF 0.00112 38.04 0.6026
ProShares UltraPro Russell2000 0.00055 89.82 1.47873
ProShares Hedge Replication ETF 0.00016 5.92 1.47892
Vanguard Russell 2000 ETF 0 17.16 1.48801
Vanguard Russell 3000 ETF 0 31.87 1.43817
Vanguard Russell 2000 Growth ETF 0 23.05 0.60264
031.851.23



导师 职称 支付 出生年份
Dr. Francois Binette M.Sc., Ph.D. COO and Executive VP for Research & Development 504.38k 1964 (61 年)
Dr. Serhat Gümrükcü Co-Founder & Inventor N/A
Mr. Greg Duczynski Ph.D. Senior Vice President for Clinical Operations N/A
Hon. Mark R. Dybul M.D. CEO, Director & Member of HBV Scientific Advisory Board 764.58k 1963 (62 年)
Mr. Simon Tarsh Interim Chief Financial Officer N/A 1961 (64 年)

地址: United States, Los Angeles. CA, 2080 Century Park East - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://www.renovarobio.com